How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice

Table 2 Practical issues about CGRP(r) MoAbs versus other migraine preventive treatments with established efficacy

	CGRP(r) MoAbs	Antiepileptics	β-blockers	OnabotulinumtoxinA
Route of administration	Intravenous or subcutaneous injection	Oral	Oral	Intramuscular
Dosing frequency	Monthly or quarterly	≥1 daily	≥ 1 daily	Quarterly
Adverse effects	Rare	Common	Infrequent	Rare
Pregnancy and nursing	Contraindicated	Contraindicated	Possible with caution in the first trimester of pregnancy Not recommended during breastfeeding	Contraindicated
Costs	High	Low	Very low	Medium

CGRP(r) indicates Calcitonin gene-related peptide (receptor), MoAbs Monoclonal antibodies

ISSN: 1129-2377